These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33190829)

  • 21. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
    Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
    Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line.
    Hagiwara K; Kunishima S; Iida H; Miyata Y; Naoe T; Nagai H
    Apoptosis; 2015 Jul; 20(7):975-85. PubMed ID: 25835755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of thalidomide and lenalidomide in mantle cell lymphoma.
    Richardson SJ; Eve HE; Copplestone JA; Dyer MJ; Rule SA
    Acta Haematol; 2010; 123(1):21-9. PubMed ID: 19907157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
    Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S
    Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
    Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
    J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines.
    Kolbinger FR; Koeneke E; Ridinger J; Heimburg T; Müller M; Bayer T; Sippl W; Jung M; Gunkel N; Miller AK; Westermann F; Witt O; Oehme I
    Arch Toxicol; 2018 Aug; 92(8):2649-2664. PubMed ID: 29947893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas.
    Balasubramanian S; Ramos J; Luo W; Sirisawad M; Verner E; Buggy JJ
    Leukemia; 2008 May; 22(5):1026-34. PubMed ID: 18256683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
    Trivedi P; Adhikari N; Amin SA; Bobde Y; Ganesh R; Jha T; Ghosh B
    Eur J Pharm Sci; 2019 Oct; 138():105046. PubMed ID: 31421254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation.
    Rettig I; Koeneke E; Trippel F; Mueller WC; Burhenne J; Kopp-Schneider A; Fabian J; Schober A; Fernekorn U; von Deimling A; Deubzer HE; Milde T; Witt O; Oehme I
    Cell Death Dis; 2015 Feb; 6(2):e1657. PubMed ID: 25695609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.
    Vekaria PH; Kumar A; Subramaniam D; Dunavin N; Vallurupalli A; Schoenen F; Ganguly S; Anant S; McGuirk JP; Jensen RA; Rao R
    Leukemia; 2019 Jul; 33(7):1675-1686. PubMed ID: 30664664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma.
    Bhatt S; Matthews J; Parvin S; Sarosiek KA; Zhao D; Jiang X; Isik E; Letai A; Lossos IS
    Blood; 2015 Sep; 126(13):1555-64. PubMed ID: 26194763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity.
    Neumann F; Acker F; Schormann C; Pfreundschuh M; Bittenbring JT
    Cancer Immunol Immunother; 2018 Nov; 67(11):1709-1718. PubMed ID: 30132083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Son MP; Attkisson E; Dent P; Fisher RI; Friedberg JW; Grant S
    Mol Cancer Ther; 2011 Sep; 10(9):1686-97. PubMed ID: 21750224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.
    Yan W; Liu S; Xu E; Zhang J; Zhang Y; Chen X; Chen X
    Oncogene; 2013 Jan; 32(5):599-609. PubMed ID: 22391568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
    Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
    Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.